IP Library Granted Patent US 9,155,718
Granted Patent B2
US 9,155,718 · App. 14/504,159 · Granted Oct 13, 2015

Treatment of sleep disturbances

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,155,718
App. No.
14/504,159
Granted
Oct 13, 2015
Kind
B2
Abstract

The present invention provides a new composition for treating pain-associated sleep disturbances, especially shortened sleep duration, comprising ibuprofen and diphenhydramine. The composition is further prepared as a bilayer tablet or caplet, or alternatively as a soft gelatin capsule composition, to prevent interaction between the active ingredients.

Claims (23)

1. A liquid composition comprising ibuprofen and diphenhydramine in amounts effective to treat a pain-associated sleep disturbance, wherein the liquid composition consists of:

about 200 to about 400 mg of ibuprofen;

about 10 to about 50 mg of diphenhydramine;

polyethylene glycol;

potassium hydroxide; and

water;

wherein the liquid composition is formulated inside a soft gelatin capsule, and wherein the polyethylene glycol reduces interaction between the ibuprofen and the diphenhydramine inside the soft gelatin capsule.

2. The liquid composition of claim 1 , wherein the ibuprofen and diphenhydramine are dissolved in the polyethylene glycol, potassium hydroxide and water solution.

3. The liquid composition of claim 1 , wherein the diphenhydramine is present as diphenhydramine HCl or diphenyhydramine citrate.

4. The liquid composition of claim 3 , wherein the diphenhydramine HCl is present in a range from about 12.5 mg to about 50 mg.

5. The liquid composition of claim 4 , wherein the diphenhydramine HCl is present in a range from about 25 mg to about 50 mg.

6. The liquid composition of claim 5 , wherein the diphenhydramine HCl is present in an amount of about 25 mg.

7. The liquid composition of claim 3 , wherein the diphenhydramine citrate is present in a range from about 19 mg to 38 mg.

8. The liquid composition of claim 7 , wherein the diphenhydramine citrate is present in an amount of 38 mg.

9. The liquid composition of claim 1 , wherein the ibuprofen is present in a range from about 200 mg to about 300 mg.

10. The liquid composition of claim 1 , wherein the ibuprofen is present in an amount about 200 mg.

11. A liquid composition formulated inside a soft gelatin capsule, wherein the liquid composition consists of:

about 200 mg ibuprofen,

about 38 mg diphenhydramine,

polyethylene glycol,

potassium hydroxide, and

water;

wherein the polyethylene glycol reduces interaction between the ibuprofen and the diphenhydramine inside the soft gelatin capsule.

Assignments (2)
MERGER AND CHANGE OF NAME Recorded Apr 6, 2022
From: PF CONSUMER HEALTHCARE 1 LLC; GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC
To: GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC
Reel/Frame 059620/0041 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2019
From: WYETH LLC
To: PF CONSUMER HEALTHCARE 1 LLC
Reel/Frame 050727/0184 →